PT  - JOURNAL ARTICLE
AU  - Mercolli, Lorenzo
AU  - Mingels, Clemens
AU  - Manzini, Giulia
AU  - Cumming, Paul
AU  - Zeimpekis, Konstantinos
AU  - Xue, Song
AU  - Alberts, Ian
AU  - Uehlinger, Dominik
AU  - Rominger, Axel
AU  - Shi, Kuangyu
AU  - Afshar-Oromieh, Ali
TI  - [<sup>177</sup>Lu]Lu-PSMA-617 Therapy in a Patient with Chronic Kidney Disease
AID  - 10.2967/jnumed.123.265577
DP  - 2023 Oct 01
TA  - Journal of Nuclear Medicine
PG  - 1570--1573
VI  - 64
IP  - 10
4099  - http://jnm.snmjournals.org/content/64/10/1570.short
4100  - http://jnm.snmjournals.org/content/64/10/1570.full
SO  - J Nucl Med2023 Oct 01; 64
AB  - We report the dosimetric evaluation of prostate-specific membrane antigen–based radioligand therapy (RLT) for metastatic prostate cancer in a patient with autosomal-dominant polycystic kidney disease. Methods: The patient received hemodialysis during each of 6 RLT cycles while staying as an inpatient. We used voxel dosimetry and blood sampling for the dose calculation. Results: The patient responded well to the RLT, as indicated by the prostate-specific antigen level decreasing from 298 to 7.1 ng/mL. The doses per cycle ranged from 0.19 to 0.4 Gy/GBq for the parotid gland, 0.14 to 0.28 Gy/GBq for the submandibular gland, 0.03 to 0.11 Gy/GBq per kidney, and 0.10 to 0.15 Gy/GBq for the red bone marrow. Conclusion: This case suggests that [177Lu]Lu-PSMA–based RLT can be applied successfully and safely to a patient with chronic kidney disease undergoing hemodialysis.